Home > Riviste > Journal of Neurosurgical Sciences > Fascicoli precedenti > Journal of Neurosurgical Sciences 2019 August;63(4) > Journal of Neurosurgical Sciences 2019 August;63(4):450-7

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW   

Journal of Neurosurgical Sciences 2019 August;63(4):450-7

DOI: 10.23736/S0390-5616.19.04701-5

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

The management of low-grade gliomas in adults

Ramin A. MORSHED, Jacob S. YOUNG, Shawn L. HERVEY-JUMPER, Mitchel S. BERGER

Department of Neurological Surgery, University of California, San Francisco, CA, USA



Low grade gliomas (LGGs) are WHO grade II tumors that affect mostly adult patients and include diffuse astrocytomas and oligodendrogliomas. New diagnostic criteria based on histology and molecular characterization with IDH mutation status and 1p/19q codeletion status have provided further categorization of these tumors and additional insights into prognosis and treatment response. In general, the current management of LGG favors maximum upfront resection with consideration of combined chemoradiation for patients deemed “high risk.” In this review, we summarize the defining molecular features, important prognostic factors, recommended pre-operative imaging work-up, as well as therapeutic management of WHO Grade II low grade gliomas in adults.


KEY WORDS: Glioma; Radiotherapy; Drug therapy; Temozolomide; Vincristine; Procarbazine

inizio pagina